Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Jul-Aug;17(4):287-92.
doi: 10.1080/10550490802138814.

Preliminary study of buprenorphine and bupropion for opioid-dependent smokers

Marc E Mooney  1 , James Poling, Gerardo Gonzalez, Kishor Gonsai, Thomas Kosten, Mehmet Sofuoglu
Affiliations
Randomized Controlled Trial

Preliminary study of buprenorphine and bupropion for opioid-dependent smokers

Marc E Mooney et al. Am J Addict. 2008 Jul-Aug.

Abstract

In this double-blind, placebo-controlled trial, bupropion (BUPRO, 300 mg/day) was compared to placebo (PBO) for the concurrent treatment of opioid and tobacco addiction in 40 opioid-dependent smokers stabilized on buprenorphine (BUPRE, 24 mg/day). Participants received contingent, monetary reinforcement for abstinence from smoking, illicit opioids, and cocaine. Significant differences in treatment retention were observed (BUPRE+BUPRO, 58%; BUPRE+PBO, 90%). BUPRO treatment was not more effective than placebo for abstinence from tobacco, opioids, or cocaine in BUPRE-stabilized patients. These preliminary findings do not support the efficacy of BUPRO, in combination with BUPRE, for the concurrent treatment of opioid and tobacco addiction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Retention rates by medication group in the 10-week treatment period. Fewer participants in the BUPRE+BUPRO condition were retained at a lower rate (58%) than those in the BUPRE+PBO (90%), p = .0241.
Figure 2
Figure 2
Panel A. Combined abstinence rates in the 10-week treatment period, adjusted for baseline CO-level as well as days of illicit opioid and cocaine use in the 30-days preceding enrollment. Panel B. Smoking abstinence rates in the 10-week treatment period, adjusted for baseline CO-level. Panel C. Illicit opioid abstinence rates in the 10-week treatment period, adjusted for days of illicit opioid use in the 30-days preceding enrollment. Panel D. Cocaine abstinence rates in the 10-week treatment period, adjusted for days of cocaine use in the 30-days preceding enrollment. Abstinence rates differed as function of biweek, p<.001 and medication × biweek. p = .0259.
See this image and copyright information in PMC

References

    1. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106–123. - PMC - PubMed
    1. McCool RM, Richter KP, Choi WS. Benefits of and barriers to providing smoking treatment in methadone clinics: findings from a national study. Am J Addict. 2005;14(4):358–366. - PubMed
    1. Pomerleau OF. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology. 1998;23(2):115–130. - PubMed
    1. Mello NK, Lukas SE, Mendelson JH. Buprenorphine effects on cigarette smoking. Psychopharmacology (Berl) 1985;86(4):417–425. - PubMed
    1. Mello NK, Mendelson JH, Sellers ML, Kuehnle JC. Effects of heroin self-administration on cigarette smoking. Psychopharmacology (Berl) 1980;67(1):45–52. - PubMed

Publication types

MeSH terms